MPM Capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas.
MPM is currently investing out of BV2014, its most recent venture fund.
In 2015 MPM partnered with UBS to create the UBS Oncology Impact Fund (OIF), an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities.
OIF will support both basic cancer research as well as access to cancer care in developing countries.
450 Kendall Street
02142 United States